Withdrawal of Invasive Home Mechanical Ventilation in Patients with Advanced Amyotrophic Lateral Sclerosis: Ten Years of Danish Experience

2012 ◽  
Vol 15 (2) ◽  
pp. 205-209 ◽  
Author(s):  
Pia Sander Dreyer ◽  
Michael Felding ◽  
Charlotte Sønderskov Klitnæs ◽  
Charlotte Kirkegård Lorenzen
CHEST Journal ◽  
2000 ◽  
Vol 117 (3) ◽  
pp. 924 ◽  
Author(s):  
Emilio Servera ◽  
Elia Gómez-Merino ◽  
Diego Pérez ◽  
Julio Marín

1993 ◽  
Vol 7 (4_suppl) ◽  
pp. 49-64 ◽  
Author(s):  
Edward Anthony Oppenheimer

As respiratory function starts to deteriorate in those with amyotrophic lateral sclerosis, one of the principal questions that has to be answered is whether it is appropriate to provide ventilatory support. Although expensive, it is perfectly feasible to provide this at home, and this article examines many of the issues surrounding home mechanical ventilation.


CHEST Journal ◽  
2005 ◽  
Vol 127 (6) ◽  
pp. 2132-2138 ◽  
Author(s):  
Eva Farrero ◽  
Enric Prats ◽  
Mónica Povedano ◽  
J. Antonio Martinez-Matos ◽  
Frederic Manresa ◽  
...  

Healthcare ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 142
Author(s):  
Ondřej Gajdoš ◽  
Martin Rožánek ◽  
Gleb Donin ◽  
Vojtěch Kamenský

Amyotrophic lateral sclerosis is a disease with rapid progression. The use of mechanical ventilation helps to manage symptoms and delays death. Use in a home environment could reduce costs and increase quality of life. The aim of this study is a cost–utility analysis of home mechanical ventilation in adult patients with amyotrophic lateral sclerosis from the perspective of healthcare payers in the Czech Republic. The study evaluates home mechanical ventilation (HMV) and mechanical ventilation (MV) in a healthcare facility. A Markov model was compiled for evaluation in a timeframe of 10 years. Model parameters were obtained from the literature and opinions of experts from companies dealing with home care and home mechanical ventilation. The cost–utility analysis was carried out at the end of the study and results are presented in incremental cost–utility ratio (ICUR) using quality-adjusted life-years. Uncertainty was assessed by one-way sensitivity analysis and scenario analysis. The cumulative costs of HMV are CZK 1,877,076 and the cumulative costs of the MV are CZK 7,386,629. The cumulative utilities of HMV are 12.57 quality-adjusted life year (QALY) and the cumulative utilities of MV are 11.32 QALY. The ICUR value is CZK-4,403,259. The results of this study suggest that HMV is cost effective.


Sign in / Sign up

Export Citation Format

Share Document